Condition: Pancreatic Adenocarcinoma · Pancreatic Cancer · Pancreatic Adenosquamous Carcinoma · Sponsor: Diakonos Oncology Corporation
This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
This description comes directly from the study's public registry record.
Benjamin Musher, MD · 713-798-4292 · blmusher@bcm.edu
Always discuss trial participation with your own doctor first.
| Baylor College of Medicine Medical Center - McNair Campus | Houston, Texas, United States | Recruiting |
| Baylor St. Lukes Medical Center | Houston, Texas, United States | Recruiting |
| Dan L. Duncan Cancer Center at Baylor College of Medicine | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04157127